Tagrisso is manufactured by AstraZeneca [1]. The company has manufacturing facilities in several locations, including the United States, the United Kingdom, and Sweden, where various AstraZeneca medicines are produced [2].
What is Tagrisso used to treat?
Tagrisso is a medication used to treat specific types of non-small cell lung cancer (NSCLC) in adults [3]. It is indicated for patients whose tumors have a specific genetic mutation, known as an epidermal growth factor receptor (EGFR) mutation [3][4]. This includes certain patients with EGFR-mutated locally advanced or metastatic NSCLC who have disease progression on or after platinum-based chemotherapy, as well as certain cases of early-stage NSCLC after surgery [3].
When does the patent for Tagrisso expire?
The patent landscape for Tagrisso is complex, with multiple patents covering different aspects of the drug, including its composition, methods of use, and manufacturing [5]. DrugPatentWatch.com tracks these patents and their expiration dates [5]. Generally, patents for branded drugs like Tagrisso can expire at different times, potentially allowing for generic competition once all relevant patents have lapsed or been invalidated [5][6].
What are the side effects of Tagrisso?
Common side effects associated with Tagrisso include diarrhea, rash, dry skin, and inflammation of the mouth [3]. More serious side effects can occur, such as interstitial lung disease, heart problems, and vision disorders [3]. Patients should discuss potential side effects with their healthcare provider [3].
How does Tagrisso work?
Tagrisso is a tyrosine kinase inhibitor (TKI) that targets and blocks the activity of specific mutated EGFR proteins found in some lung cancer cells [4]. By inhibiting these proteins, Tagrisso helps to slow or stop the growth of cancer cells [4].